Bionano Net Cash Flow from Financing vs Issuance Purchase of Equity Shares Analysis

BNGO Stock

USD 0.87 0.11 11.22%

Trend analysis of Bionano Genomics balance sheet accounts such as Short Long Term Debt Total of 92.3 M, Other Current Liabilities of 8.9 M or Total Current Liabilities of 105 M provides information on Bionano Genomics' total assets, liabilities, and equity, which is the actual value of Bionano Genomics to its prevalent stockholders. By breaking down trends over time using Bionano Genomics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Total Assets Net Tangible Assets

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bionano Genomics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Bionano Stock, please use our How to Invest in Bionano Genomics guide.

About Bionano Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Bionano Genomics at a specified time, usually calculated after every quarter, six months, or one year. Bionano Genomics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Bionano Genomics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Bionano currently owns. An asset can also be divided into two categories, current and non-current.

Bionano Genomics Balance Sheet Chart

Bionano Genomics Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Bionano Genomics uses and utilizes its capital. It also shows what exactly a company owns and owes.

At this time, Bionano Genomics' Net Debt is very stable compared to the past year. As of the 16th of April 2024, Cash is likely to grow to about 55.7 M, while Total Assets are likely to drop about 142.9 M.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Add Fundamental

Total Assets

Total assets refers to the total amount of Bionano Genomics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Bionano Genomics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Bionano Genomics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Bionano Genomics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most indicators from Bionano Genomics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Bionano Genomics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bionano Genomics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Bionano Stock, please use our How to Invest in Bionano Genomics guide.At this time, Bionano Genomics' Tax Provision is very stable compared to the past year. As of the 16th of April 2024, Selling General Administrative is likely to grow to about 98.2 M, while Enterprise Value Over EBITDA is likely to drop (0.83).

	2021	2022	2023	2024 (projected)
Interest Expense	927K	298K	5.1M	5.4M
Depreciation And Amortization	177K	1.3M	13.7M	14.4M

Interest Expense Depreciation And Amortization

Bionano Genomics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Long Term Debt Total	Non Current Liabilities Total	Capital Surpluse	Inventory	Other Current Assets	Other Stockholder Equity
Total Assets		0.35	0.64	0.47	0.98	0.79	0.95	0.8	0.84	0.15	-0.67	0.94	0.42	0.95	0.01	0.72	0.96	0.67	0.85	0.86	0.72	-0.35	0.86	0.8	0.91	0.17
Short Long Term Debt Total	0.35		0.04	0.98	0.24	0.78	0.56	0.78	0.42	0.83	-0.91	0.49	0.89	0.31	0.59	0.48	0.3	0.68	0.73	0.76	0.48	-0.39	0.76	0.68	0.48	0.14
Other Current Liab	0.64	0.04		0.23	0.61	0.59	0.45	0.6	0.77	0.21	-0.39	0.68	-0.1	0.82	0.24	0.23	0.45	0.27	0.5	0.53	0.23	0.2	0.51	0.71	0.73	0.38
Total Current Liabilities	0.47	0.98	0.23		0.36	0.88	0.64	0.87	0.54	0.87	-0.95	0.62	0.82	0.47	0.59	0.53	0.39	0.75	0.79	0.83	0.53	-0.35	0.84	0.8	0.6	0.22
Total Stockholder Equity	0.98	0.24	0.61	0.36		0.71	0.92	0.72	0.77	0.01	-0.58	0.89	0.36	0.92	-0.12	0.69	0.96	0.59	0.79	0.79	0.69	-0.4	0.8	0.73	0.85	0.1
Other Liab	0.79	0.78	0.59	0.88	0.71		0.86	1.0	0.82	0.69	-0.95	0.87	0.66	0.81	0.51	0.59	0.68	0.77	0.92	0.97	0.59	-0.3	0.97	0.96	0.86	0.19
Net Tangible Assets	0.95	0.56	0.45	0.64	0.92	0.86		0.86	0.76	0.29	-0.78	0.88	0.64	0.85	0.13	0.72	0.95	0.69	0.91	0.92	0.72	-0.46	0.93	0.8	0.83	0.13
Property Plant And Equipment Net	0.8	0.78	0.6	0.87	0.72	1.0	0.86		0.83	0.66	-0.95	0.88	0.68	0.82	0.49	0.62	0.7	0.76	0.94	0.98	0.62	-0.3	0.97	0.97	0.88	0.24
Current Deferred Revenue	0.84	0.42	0.77	0.54	0.77	0.82	0.76	0.83		0.36	-0.7	0.86	0.37	0.89	0.32	0.55	0.71	0.59	0.77	0.81	0.55	-0.19	0.79	0.85	0.91	0.37
Net Debt	0.15	0.83	0.21	0.87	0.01	0.69	0.29	0.66	0.36		-0.72	0.34	0.48	0.22	0.78	0.13	0.03	0.53	0.44	0.53	0.13	-0.03	0.53	0.61	0.33	0.22
Retained Earnings	-0.67	-0.91	-0.39	-0.95	-0.58	-0.95	-0.78	-0.95	-0.7	-0.72		-0.8	-0.83	-0.68	-0.47	-0.69	-0.57	-0.83	-0.93	-0.95	-0.69	0.43	-0.95	-0.91	-0.8	-0.16
Accounts Payable	0.94	0.49	0.68	0.62	0.89	0.87	0.88	0.88	0.86	0.34	-0.8		0.49	0.96	0.1	0.81	0.83	0.83	0.89	0.9	0.81	-0.38	0.91	0.91	0.98	0.19
Cash	0.42	0.89	-0.1	0.82	0.36	0.66	0.64	0.68	0.37	0.48	-0.83	0.49		0.31	0.29	0.65	0.44	0.63	0.79	0.75	0.65	-0.59	0.75	0.57	0.48	0.03
Non Current Assets Total	0.95	0.31	0.82	0.47	0.92	0.81	0.85	0.82	0.89	0.22	-0.68	0.96	0.31		0.08	0.67	0.83	0.67	0.82	0.84	0.67	-0.27	0.84	0.88	0.96	0.2
Non Currrent Assets Other	0.01	0.59	0.24	0.59	-0.12	0.51	0.13	0.49	0.32	0.78	-0.47	0.1	0.29	0.08		-0.28	-0.07	0.07	0.25	0.35	-0.28	0.41	0.31	0.38	0.15	0.18
Long Term Debt	0.72	0.48	0.23	0.53	0.69	0.59	0.72	0.62	0.55	0.13	-0.69	0.81	0.65	0.67	-0.28		0.68	0.85	0.79	0.72	1.0	-0.7	0.75	0.65	0.77	0.11
Cash And Short Term Investments	0.96	0.3	0.45	0.39	0.96	0.68	0.95	0.7	0.71	0.03	-0.57	0.83	0.44	0.83	-0.07	0.68		0.56	0.78	0.78	0.68	-0.37	0.78	0.64	0.77	0.14
Net Receivables	0.67	0.68	0.27	0.75	0.59	0.77	0.69	0.76	0.59	0.53	-0.83	0.83	0.63	0.67	0.07	0.85	0.56		0.76	0.77	0.85	-0.63	0.82	0.79	0.79	-0.04
Common Stock Total Equity	0.85	0.73	0.5	0.79	0.79	0.92	0.91	0.94	0.77	0.44	-0.93	0.89	0.79	0.82	0.25	0.79	0.78	0.76		0.99	0.79	-0.46	0.98	0.91	0.89	0.21
Common Stock Shares Outstanding	0.86	0.76	0.53	0.83	0.79	0.97	0.92	0.98	0.81	0.53	-0.95	0.9	0.75	0.84	0.35	0.72	0.78	0.77	0.99		0.72	-0.4	0.99	0.94	0.89	0.22
Long Term Debt Total	0.72	0.48	0.23	0.53	0.69	0.59	0.72	0.62	0.55	0.13	-0.69	0.81	0.65	0.67	-0.28	1.0	0.68	0.85	0.79	0.72		-0.7	0.75	0.65	0.77	0.11
Non Current Liabilities Total	-0.35	-0.39	0.2	-0.35	-0.4	-0.3	-0.46	-0.3	-0.19	-0.03	0.43	-0.38	-0.59	-0.27	0.41	-0.7	-0.37	-0.63	-0.46	-0.4	-0.7		-0.47	-0.33	-0.36	0.33
Capital Surpluse	0.86	0.76	0.51	0.84	0.8	0.97	0.93	0.97	0.79	0.53	-0.95	0.91	0.75	0.84	0.31	0.75	0.78	0.82	0.98	0.99	0.75	-0.47		0.94	0.89	0.15
Inventory	0.8	0.68	0.71	0.8	0.73	0.96	0.8	0.97	0.85	0.61	-0.91	0.91	0.57	0.88	0.38	0.65	0.64	0.79	0.91	0.94	0.65	-0.33	0.94		0.93	0.22
Other Current Assets	0.91	0.48	0.73	0.6	0.85	0.86	0.83	0.88	0.91	0.33	-0.8	0.98	0.48	0.96	0.15	0.77	0.77	0.79	0.89	0.89	0.77	-0.36	0.89	0.93		0.19
Other Stockholder Equity	0.17	0.14	0.38	0.22	0.1	0.19	0.13	0.24	0.37	0.22	-0.16	0.19	0.03	0.2	0.18	0.11	0.14	-0.04	0.21	0.22	0.11	0.33	0.15	0.22	0.19

Click cells to compare fundamentals

Bionano Genomics Account Relationship Matchups

Bionano Genomics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	30.2M	60.4M	377.1M	307.5M	214.4M	142.9M
Short Long Term Debt Total	20.0M	16.3M	10.7M	11.7M	87.9M	92.3M
Other Current Liab	3.2M	5.6M	9.7M	19.9M	8.1M	8.9M
Total Current Liabilities	26.3M	8.9M	21.8M	35.9M	100.0M	105.0M
Total Stockholder Equity	3.6M	35.1M	337.1M	249.4M	96.2M	89.9M
Other Liab	227.1K	97.9K	9.2M	13.1M	15.1M	15.8M
Net Tangible Assets	3.6M	26.4M	337.1M	172.1M	197.9M	207.8M
Property Plant And Equipment Net	1.9M	4.9M	20.9M	29.0M	32.5M	34.1M
Current Deferred Revenue	357.5K	415.5K	684K	871K	783K	555.6K
Net Debt	2.7M	(22.1M)	(13.9M)	6.6M	34.9M	36.6M
Retained Earnings	(102.6M)	(143.7M)	(216.1M)	(348.7M)	(581.2M)	(552.1M)
Accounts Payable	2.7M	2.9M	9.7M	12.5M	10.4M	5.9M
Cash	17.3M	38.4M	24.6M	5.1M	53.1M	55.7M
Non Current Assets Total	1.9M	13.7M	104.7M	150.2M	74.3M	48.6M
Non Currrent Assets Other	(1.9M)	102.6K	749K	2.8M	7.4M	7.8M
Cash And Short Term Investments	17.3M	38.4M	250.6M	113.2M	101.9M	74.8M
Net Receivables	6.3M	2.8M	4.9M	7.0M	9.7M	5.6M
Common Stock Total Equity	3.4K	19.0K	29K	30K	34.5K	36.2K
Common Stock Shares Outstanding	1.5M	10.4M	27.7M	28.9M	34.2M	35.9M
Liabilities And Stockholders Equity	30.3M	60.4M	377.1M	307.5M	214.4M	142.9M
Non Current Liabilities Total	335.0K	16.4M	18.1M	22.2M	18.2M	16.2M
Capital Surpluse	106.2M	178.7M	553.7M	599.2M	689.1M	723.5M
Inventory	3.4M	3.3M	12.4M	29.8M	22.9M	24.0M
Other Current Assets	1.2M	2.2M	4.5M	7.3M	5.7M	3.2M
Other Stockholder Equity	106.2M	178.7M	553.7M	599.2M	677.3M	711.2M
Total Liab	26.6M	25.4M	40.0M	58.1M	118.2M	124.2M
Property Plant And Equipment Gross	1.9M	4.9M	10.3M	29.0M	51.6M	54.1M
Total Current Assets	28.3M	46.8M	272.4M	157.3M	140.1M	94.3M
Accumulated Other Comprehensive Income	(5.2M)	(6.3M)	(539K)	(1.1M)	23K	24.2K
Non Current Liabilities Other	808.4K	44.5K	18.0M	22.1M	10.9M	8.4M
Common Stock	3.4K	19.0K	29K	30K	5K	4.8K
Property Plant Equipment	1.9M	4.9M	10.3M	18.0M	20.7M	21.8M
Net Invested Capital	23.7M	51.4M	337.1M	249.4M	166.0M	126.2M
Net Working Capital	1.9M	37.8M	250.6M	121.4M	40.1M	72.4M
Retained Earnings Total Equity	(102.6M)	(143.7M)	(216.1M)	(348.7M)	(313.8M)	(298.2M)
Deferred Long Term Liab	182.6K	97.9K	146K	127K	114.3K	137.3K

Bionano Genomics Investors Sentiment

The influence of Bionano Genomics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Bionano. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.

Investor biases related to Bionano Genomics' public news can be used to forecast risks associated with an investment in Bionano. The trend in average sentiment can be used to explain how an investor holding Bionano can time the market purely based on public headlines and social activities around Bionano Genomics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.

Bionano Genomics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Bionano Genomics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Bionano Genomics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Bionano Genomics.

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Bionano Genomics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Bionano Genomics' short interest history, or implied volatility extrapolated from Bionano Genomics options trading.

Pair Trading with Bionano Genomics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bionano Genomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bionano Genomics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Bionano Stock

0.73

VRTX

Vertex Pharmaceuticals Financial Report 6th of May 2024

Pair Corr

Moving against Bionano Stock

0.7	ERNA	Eterna Therapeutics	Pair Corr
0.7	NVO	Novo Nordisk AS Financial Report 2nd of May 2024	Pair Corr
0.69	A	Agilent Technologies Financial Report 28th of May 2024	Pair Corr
0.62	DSGN	Design Therapeutics Financial Report 14th of May 2024	Pair Corr
0.58	LLY	Eli Lilly Sell-off Trend	Pair Corr

The ability to find closely correlated positions to Bionano Genomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bionano Genomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bionano Genomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bionano Genomics to buy it.

The correlation of Bionano Genomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bionano Genomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bionano Genomics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Bionano Genomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Bionano Genomics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bionano Genomics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bionano Genomics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bionano Genomics Stock:

How To Invest In Bionano

Details

Is Bionano Stock a good investment?

Details

What is Bionano Genomics' Net Worth?

Details

Largest Life Sciences Tools & Services Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

To learn how to invest in Bionano Stock, please use our How to Invest in Bionano Genomics guide.

Note that the Bionano Genomics information on this page should be used as a complementary analysis to other Bionano Genomics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.

Complementary Tools for Bionano Stock analysis

When running Bionano Genomics' price analysis, check to measure Bionano Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bionano Genomics is operating at the current time. Most of Bionano Genomics' value examination focuses on studying past and present price action to predict the probability of Bionano Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bionano Genomics' price. Additionally, you may evaluate how the addition of Bionano Genomics to your portfolios can decrease your overall portfolio volatility.

	Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
	Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital
	Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated
	My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios
	Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
	Share Portfolio Track or share privately all of your investments from the convenience of any device
	Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
	Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
	Equity Valuation Check real value of public entities based on technical and fundamental data
	Portfolio Anywhere Track or share privately all of your investments from the convenience of any device

Is Bionano Genomics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bionano Genomics. If investors know Bionano will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bionano Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(6.81)

Revenue Per Share

1.058

Quarterly Revenue Growth

0.305

Return On Assets

(0.33)

Return On Equity

(1.35)

The market value of Bionano Genomics is measured differently than its book value, which is the value of Bionano that is recorded on the company's balance sheet. Investors also form their own opinion of Bionano Genomics' value that differs from its market value or its book value, called intrinsic value, which is Bionano Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bionano Genomics' market value can be influenced by many factors that don't directly affect Bionano Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Bionano Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bionano Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bionano Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Bionano Net Cash Flow from Financing vs Issuance Purchase of Equity Shares Analysis

About Bionano Balance Sheet Analysis

Bionano Genomics Balance Sheet Chart

Total Assets

Total Current Liabilities

Bionano Genomics fundamental ratios Correlations

Bionano Genomics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Bionano Genomics fundamental ratios Accounts

Bionano Genomics Investors Sentiment

Pair Trading with Bionano Genomics

Moving together with Bionano Stock

Moving against Bionano Stock

Complementary Tools for Bionano Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Net	+ 1.0	Other Liab
Long Term Debt Total	+ 1.0	Long Term Debt
Common Stock Shares Outstanding	+ 0.99	Common Stock Total Equity
Capital Surpluse	+ 0.99	Common Stock Shares Outstanding
Total Stockholder Equity	+ 0.98	Total Assets
Total Current Liabilities	+ 0.98	Short Long Term Debt Total

Capital Surpluse	- 0.95	Retained Earnings
Common Stock Shares Outstanding	- 0.95	Retained Earnings
Retained Earnings	- 0.95	Property Plant And Equipment Net
Retained Earnings	- 0.95	Other Liab
Retained Earnings	- 0.95	Total Current Liabilities
Common Stock Total Equity	- 0.93	Retained Earnings